Brief: Mithra Says Delay In Donesta US NDA Filing Negatively Impacted Process To Consummate US Licensing Agreement, & Negatively Impacting Expected Revenues.

Mithra Pharmaceuticals SA

08/03/2024 06:04

March 8 (Reuters) - Mithra Pharmaceuticals SA
 MITRA.BR :
    * MITHRA: DELAY IN DONESTA® US NDA FILING NEGATIVELY
IMPACTED
PROCESS TO CONSUMMATE A US LICENSING AGREEMENT, & NEGATIVELY
IMPACTING EXPECTED REVENUES.
    * MITHRA PHARMACEUTICALS SA - APPOINTMENT OF CHRISTOPHE
MARÉCHAL,
XAVIER PAOLI AS CO-CEOS AFTER 05 MAR TERMINATION OF MANAGEMENT
AGREEMENT OF FORMER CEO
    * MITHRA: INITIATED A MONETIZATION PROCESS TO REALIZE VALUE
FROM
ITS ASSETS INVOLVING SALE OF VARIOUS SELECTED ASSETS,
PARTICULARLY ESTETRA SRL

Source text for Eikon:  ID:nGNE6yYD4h 
Further company coverage:  MITRA.BR 

 ((Reuters.Briefs@thomsonreuters.com;))